Literature DB >> 30043058

Andexxa-An Antidote for Apixaban and Rivaroxaban.

.   

Abstract

Entities:  

Year:  2018        PMID： 30043058     DOI： 10.1001/jama.2018.9257

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

Review 1.  American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period.

Authors:  Neena S Abraham; Alan N Barkun; Bryan G Sauer; James Douketis; Loren Laine; Peter A Noseworthy; Jennifer J Telford; Grigorios I Leontiadis
Journal:  J Can Assoc Gastroenterol       Date:  2022-03-17

Review 2.  Demystifying the Benefits and Harms of Anticoagulation for Atrial Fibrillation in Chronic Kidney Disease.

Authors:  Katherine G Garlo; David J R Steele; Sagar U Nigwekar; Kevin E Chan
Journal:  Clin J Am Soc Nephrol       Date:  2018-12-28       Impact factor: 8.237

3.  Spontaneous Hemorrhagic Pericardial and Pleural Effusion in a Patient Receiving Apixaban.

Authors:  Michael Cinelli; Asif Uddin; Ilirjana Duka; Armaghan Soomro; Frank Tamburrino; Foad Ghavami; James Lafferty
Journal:  Cardiol Res       Date:  2019-07-31

4.  Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study.

Authors:  Anne-Laure Sennesael; Anne-Sophie Larock; Jonathan Douxfils; Laure Elens; Gabriel Stillemans; Martin Wiesen; Max Taubert; Jean-Michel Dogné; Anne Spinewine; François Mullier
Journal:  Thromb J       Date:  2018-11-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.